IDARUCIZUMAB belongs to the group of medicines called anticoagulant reversal agents used during a medical emergency to treat severe or uncontrolled bleeding that has been caused by taking dabigatran (a medicine used to prevent blood clots).
IDARUCIZUMAB contains Idarucizumab, a humanised monoclonal antibody fragment (Fab) which rapidly traps dabigatran in order to inactivate its effect.
IDARUCIZUMAB will be administered by a healthcare professional; do not self-administer. In some cases, IDARUCIZUMAB may cause headaches, constipation, fever, low potassium levels, and confusion. Do not be reluctant to talk with your doctor if any of the side effects persist or worsen.
Consult the doctor if you are pregnant or breastfeeding. The safety and effectiveness of IDARUCIZUMAB in children have not been established. Keep the doctor informed about your health condition and medications to rule out any side effects/interactions.
To treat severe or uncontrolled bleeding that has been caused by taking dabigatran (a medicine used to prevent blood clots).
IDARUCIZUMAB belongs to the group of medicines called anticoagulant reversal agents indicated in patients treated with dabigatran (a medicine used to prevent blood clots) when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures, in life-threatening conditions or uncontrolled bleeding. IDARUCIZUMAB contains Idarucizumab, a humanised monoclonal antibody fragment (Fab) which rapidly traps dabigatran in order to inactivate its effect.
Inform the doctor if you are allergic to any of the components in IDARUCIZUMAB, if you have hereditary fructose intolerance or if you are on a sodium-restricted diet. Consult the doctor if you are pregnant or breastfeeding. Let the doctor know if you are taking any other medicines, including supplements and herbal products.
Drug-Drug Interactions: Inform the doctor if you are taking monoclonal antibodies (rozanolixizumab, efgartigimod alfa).
Drug-Food Interactions: No interactions found.
Drug-Disease Interactions: Inform the doctor if you have fructose intolerance or liver impairment.
It is not known if alcohol affects IDARUCIZUMAB. Please consult your doctor.
IDARUCIZUMAB should be given to pregnant women only if clearly needed. Inform the doctor if you are pregnant or think you may be pregnant.
Caution is advised while administering IDARUCIZUMAB to a nursing woman.
This medicine is for hospital use only.
If you have a history of liver disease, inform your doctor before receiving IDARUCIZUMAB.
If you have a history of kidney disease, inform your doctor before receiving IDARUCIZUMAB.
The safety and effectiveness of IDARUCIZUMAB in children have not been established.
Bleeding: Bleeding is the loss of blood inside or outside the body. It is the main risk associated with dabigatran treatment. Severe or uncontrolled bleeding requires immediate medical attention to prevent loss of blood. Anticoagulant reversal agents such as IDARUCIZUMAB are used to treat severe and uncontrolled bleeding.